Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/FCF ratio high or low?
The EV/FCF ratio of 11.16x is 15% below its estimated 1-year average of 13.15x, near the low end of its estimated 1-year range (10.55x–16.04x).
As of 2026-10-06T14:42:10.268Z.
Calculation as of: 2026-10-06T14:42:10.268Z.
Quote observation: 2026-10-06T14:38:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8dac276dab9b72f767ef95dff0a018bdb1655164ea652fec6d95688d7a2c4747
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
11.16x
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
25.16x
median of 167 covered companies
CURRENT VS SECTOR MEDIAN
-55.64%
vs the sector median at left
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vyome Holdings, Inc. (HIND) | $13.72M | 11.16x | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.94M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.98M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.62M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.78M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.47M | N/A | N/A | N/A | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.04M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.58M | N/A | 3.45x | 3.45x | 3.45x |
| IRIDEX Corporation (IRIX)vs › | $12.41M | N/A | 7.58x | 7.58x | 7.58x |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | N/A | 97.85x | 97.85x | 97.85x |
EV/FCF
11.2x
P/FCF
26.2x
FCF Yield
3.82%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2026-10-05 | 10.82x |
| 2026-10-02 | 10.55x |
| 2026-10-01 | 10.69x |
| 2026-09-30 | 10.82x |
| 2026-09-29 | 12.03x |
| 2026-09-28 | 12.16x |
| 2026-09-25 | 12.29x |
| 2026-09-24 | 12.56x |
| 2026-09-23 | 11.89x |
| 2026-09-22 | 11.09x |
| 2026-09-21 | 10.82x |
| 2026-09-18 | 13.10x |
| 2026-09-17 | 11.22x |
| 2026-09-16 | 11.09x |
| 2026-09-15 | 11.89x |
| 2026-09-14 | 12.56x |
| 2026-09-11 | 12.56x |
| 2026-09-10 | 13.10x |
| 2026-09-09 | 12.56x |
| 2026-09-08 | 12.96x |
| 2026-09-04 | 14.70x |
| 2026-09-03 | 14.84x |
| 2026-09-02 | 14.17x |
| 2026-09-01 | 14.03x |
| 2026-08-31 | 13.90x |
| 2026-08-28 | 14.57x |
| 2026-08-27 | 14.57x |
| 2026-08-26 | 13.90x |
| 2026-08-25 | 14.84x |
| 2026-08-24 | 14.97x |
| 2026-08-21 | 15.10x |
| 2026-08-20 | 15.51x |
| 2026-08-19 | 16.04x |
| 2026-08-18 | 15.37x |
| 2026-08-17 | 15.37x |
| 2026-08-14 | 14.17x |
| 2026-08-13 | 13.90x |
